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Abstract
The Centers for Disease Control (CDC) testing recommendations suggest universal opt-out testing in all health
care settings, including cancer clinics. The incidence of non-AIDS-defining cancers (NADCs) is on the rise among
HIV patients. However, to date, no data exist on the prevalence of HIV infection among NADC patients in the
United States. Knowledge of HIV infection may affect clinical management, prognosis, and overall patient sur-
vival and decrease new infections in the population. The purpose of this study was to determine the point
seroprevalence of HIV infection in cancer patients being seen in medical oncology clinics. A total of 634 indi-
viduals (mean age = 53.2 years) participated and were tested for HIV. None of the participants tested positive for
HIV in any of the three clinics. Using a futility analysis, the upper end of the 95% confidence interval for
prevalence of undiagnosed HIV in cancer patients was less than 0.3%. Most participants were female (59.2%) and
non-Hispanic (96.6%). The majority of study participants were white (76.5%) or African-American (17.7%). Breast
cancer (19.7%), colon cancer (10.3%), and melanoma (9.7%) were the most commonly reported non-AIDS-defining
cancers. While our study suggested that there was no occurrence of undiagnosed HIV among NADC patients, it
is important to note that our population was largely white, females with insurance and with a different distri-
bution of cancer than the most prevalent NADC among HIV patients. Furthermore, one-third of the patients did
not consent to participate and further studies are needed to assess reasons for their unwillingness along with
other populations, specifically minorities and individuals with low socioeconomic status (SES).
Human immunodeficiency virus (HIV) and acquiredimmunodeficiency syndrome (AIDS) remain leading
causes of illness and death in the United States. Since the first
case reported in 1981, the Centers for Disease Control and
Prevention (CDC) has estimated that more than 1.7 million
people in the United States have been infected with HIV
including over 600,000 who have died and approximately
1.2 million who are currently living with HIV.1 It is esti-
mated that, 20% (about 220,000) of HIV-infected individuals
are unaware of their infection and about 32% are diagnosed
late when the disease has progressed.1 Despite much effort
to reduce new infections, the annual incidence of HIV has
been stable in the past few years, with between 45,000 and
53,200 new cases between 2007 and 2010 (47,500 in 2010) in
the United States.2 This estimate is based on prevalence es-
timates primarily among high-risk individuals identified
from active surveillance among various populations in the
United States. It is of great public health importance, and yet
remains a substantial challenge, to identify individuals with
undiagnosed HIV and link them to clinical care, which will
improve their health outcomes and limit further transmission.
Individuals unaware of their HIV infection, including cancer
patients and specifically those with non-AIDS-defining cancers
(NADCs), are unable to take advantage of life-saving HIV
treatments, and may unknowingly infect others. In 2006, the
CDC revised its recommendations for HIV testing in healthcare
settings to include opt-out HIV testing as a routine part of
medical care for all patients, ages 13–64, without the necessity
for separate written consent or for pretest HIV counseling.3
However, despite the CDC’s recommendations, very few
providers have incorporated routine HIV testing into their
practice.
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Following the advent of effective antiretroviral therapy
(ART), medical treatment for HIV has been continuously im-
proving and the average life expectancy has dramatically im-
proved for HIV patients in the United States.4 The increased
lifespan of HIV patients has created a rise in the frequency of
chronic illnesses including cancer, which was not seen during
the pre-ART era.5 The ability to track the epidemic of HIV and
cancer is important as cancer is emerging as an important
cause of deaths in HIV. HIV status clearly impacts the prog-
nosis for cancer and overall survival; thus, identifying those
with cancer who are HIV infected is important so that therapy
may be effectively initiated, cancer treatment side effects and
toxicities better anticipated, and outcomes better predicted.
Most often AIDS-defining cancers are used as indicators for
targeted HIV screening. Yet it remains unknown how many
NADC patients attending oncology clinics may have undiag-
nosed (occult) HIV infection. The goal of our study was to
estimate the point prevalence of HIV infection in NADC pa-
tients as a potential source of occult HIV infections. To date, no
data exist on the prevalence of HIV infection among NADC
patients in the United States. In a pilot study conducted among
lymphoid cancer patients in a tertiary center in Nigeria, 4% of
the patients were HIV positive.6 While Kaposi sarcoma, non-
Hodgkin lymphoma, and cervical cancer are considered AIDS-
defining cancers, HIV-positive individuals are also more likely
than the general population to develop Hodgkin lymphoma,
liver cancer, anal cancer, and stomach cancer, all known to
have infectious causes.7–10 While most cancers associated with
HIV are associated with an oncogenic viral infection, there is
an increasing amount of literature suggesting a higher inci-
dence of non-viral-related cancers in HIV-positive individuals
than in the general population.11 Previous reports from the
AIDS-Cancer Registry Match study have shown the incidence
of lung cancer to be higher in individuals with AIDS than it is
for the general population.12
We conducted a study to test patients for HIV in three
oncology clinics [University of Alabama at Birmingham
(UAB), University of North Carolina (UNC)–Chapel Hill, and
University of California, San Diego (UCSD)] within NCI-
supported comprehensive cancer centers located at CFAR
Network of Integrated Clinical Systems (CNICS) institutions.
All participating individuals were required to sign informed
consent forms. Study protocols were approved by the In-
stitutional Review Board at all three universities. The patients
visiting the cancer clinic were counseled before the test about
HIV with arrangements to be referred to the HIV clinic if they
were positive. Following the standard protocol, an OraQuick
rapid HIV test (sensitivity 99.3%, specificity 99.98%) was
performed using a noninvasive mouth swab. The test was
completed while the patients waited to meet their physician
and results were delivered prior to their leaving. An indi-
vidual’s type of cancer was self-reported and confirmed from
the medical chart. Some of the patients were newly referred
and did not have a confirmed diagnosis of cancer. Demo-
graphic information and other relevant clinical information
were obtained on all tested individuals.
A total of 987 patients were approached to participate in the
study (517 at UAB, 436 at UNC, and 34 at UCSD); of these 634
(66.5%) consented: 308 (59.6%) at UAB, 326 (74.8%) at UNC,
and 34 at UCSD (Table 1). The mean age of the overall par-
ticipants was 53.2 years, with relatively older individuals in
Birmingham and younger individuals in Chapel Hill. Most
participants were female (59.2%) and non-Hispanic (96.6%).
The majority of study participants were white (76.5%) or
African-American (17.7%). Most participants did not cur-
rently smoke (74%) or drink alcohol (60%). Of those patients
who consented to participate, most (51.3%) had never been
tested for HIV. Breast cancer (19.7%), colon cancer (10.3%),
and melanoma (9.7%) were the most common self-reported
malignancies among these patients (Table 1). About one-third
of study participants reported a type of cancer, which by itself
was not frequent ( < 2%). The majority of patients paid for
medical care through private insurance (60.9%) or Medicare
(20.1%), with less than 10% of patients using Medicaid or
paying out of pocket for health services. None of the partici-
pants tested positive for HIV in any of the three clinics. Using
a futility analysis, the upper end of the 95% confidence in-
terval for prevalence of undiagnosed HIV in cancer patients
was less than 0.3% in this population in the three urban
clinical setting.
Cancers associated with immunosuppression from in-
creased age could mask an underlying HIV infection that
could go unnoticed by health care professionals. For example,
the risk for developing lung cancer increases with age and
with HIV infection.5 Older individuals with lung cancer who
do not overtly fit the risk profile of patients with HIV could
have HIV infection overlooked in management of their can-
cer. Given potential differences in the prognosis and man-
agement of cancers presenting with HIV, missing a coexisting
HIV infection could impair optimal clinical management. The
ability to track the epidemic of HIV and cancer, specifically
NADC, is important since there are potential differences in
prognosis and management of cancers presenting with HIV.
In 34 U.S. states that reported AIDS during 2004–2007, an
estimated number of AIDS-defining cancer was 7,869 and
NADC was 7,563.13 Overall, reports of NADC has increased
steadily from 1991 to 2005 and has exceeded the annual
number of AIDS-defining cancers since 2003. In the United
States, lung cancer, anal cancer, liver cancer, and Hodgkin
lymphoma are the most prevalent NADCs among HIV pa-
tients.13 However, in our study, breast cancer, colon cancer,
esophageal cancer, and lung cancer were the four most
prevalent cancers. Based on the national survey of 34 states in
the United States during 2004–2007, these cancers comprised
only 7.5%, 6.2%, 1.1%, and 20.7%, respectively, of the 2191
NADC reported.13 Thus, the oversampling of patients with
these cancers (low prevalence other than lung cancer) in our
population might explain why we did not observe any HIV-
positive patients. Following the IRB guidelines, we were not
able to determine the distribution of the cancer type among
those who did not consent to participate in the study.
The prevalence of HIV infection in the general adult pop-
ulation in the United States is estimated to be 0.45% and as
high as 2.1% among heterosexuals living in high-poverty
urban areas.14 Although we had enough power to detect a few
undiagnosed HIV + individuals among our sample size of 634
in the three sites, caution is required in interpreting and
generalizing the results. Our population was composed lar-
gely of white, female, and insured individuals, whereas the
epidemic of HIV seems more prevalent among black, male,
and uninsured individuals. As described above, the patient
pool of cancer type is different than the prevalent NADC
observed among HIV patients. Of note, one-third of the pa-
tients did not consent to participate, so their cancer type could
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not be known. In one study using the discarded blood sam-
ples in an urban emergency department, it was found that the
prevalence of undiagnosed HIV was higher in individuals
who declined HIV screening versus those who consented (3%
vs. 0.7%).15 Thus, further studies are required to assess the
reasons for patients who opt out of HIV testing.
Some of the patients approached did not believe that they
were at risk for HIV; others were too sick and had several
clinical tests to be performed and did not have time, interest, or
energy for additional tests. Most cancer patients are accompa-
nied to the clinic and it is possible that they may not feel
comfortable being tested for HIV because of the stigma asso-
ciated with having to reveal their risky behaviors to their
partner. Revealing their HIV status to their primary partner
might be a significant barrier preventing individuals from en-
rolling in our study. Male self-disclosure of HIV-positive ser-
ostatus to a primary sex partner ranges from 67 to 88%,
suggesting that over 25% of individuals with HIV-positive
partners do not know that they are at risk of contracting HIV.16
Other studies have reported that 17–32% of both men and
women fail to disclose their serostatus to their partners.17 The
FDA recently approved a take home OraQuick test, and per-
haps this may provide an option for everyone to be tested in
private and seek medical care. However, it is important to ed-
ucate everyone of the availability of this test to achieve the goal.
Our study population is composed of individuals with high
socioeconomic status (SES), as evident from the large pro-
portion of people with private insurance or Medicare cover-
age (81.0%), and might not represent the population with
occult HIV in the United States. Low SES is associated with
less access to health care, lower levels of education, and in-
creased risk of contracting HIV. While our study suggested
that there was no occurrence of occult HIV among NADC
patients, further studies are needed to assess the reasons for
the unwillingness of one-third of these patients to participate
and also how the prevalence could vary in other populations,
specifically minorities and individuals with low SES. Provi-
ders need to increase HIV testing with their cancer patients,
especially since many will undergo immunosuppressive
chemotherapy and radiotherapy.
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